Payment overview · 2025
General Payments
$785.54
47 reported records · 14 companies
Healthcare provider profile · identity verified
Kevin D Hale, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1922101716
Verified facts
What the public records show
CMS Open Payments records show Kevin D Hale, M.D. received $785.54 in general payments during 2025 across 47 reported records.
ABBVIE INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.86 | 32.7% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.61 | 14.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.78 | 11.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.03 | 9.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.79 | 9.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.33 | 5.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.58 | 2.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.43 | 2.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.82 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.31 | 2.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.74 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.41 | 1.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.20 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.65 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $785.54 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $131.98 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.88 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.24 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.55 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.03 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $70.79 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 604 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 448 | 137 |
| Omeprazole | Omeprazole | 325 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 89 |
| Clonazepam | Clonazepam | 287 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 83 |
| Gabapentin | Gabapentin | 258 | 59 |
| Losartan Potassium | Losartan Potassium | 217 | 60 |
| Tramadol Hcl | Tramadol Hcl | 205 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 53 |
| Alprazolam | Alprazolam | 184 | 32 |
| Potassium Chloride | Potassium Chloride | 184 | 46 |
| Allopurinol | Allopurinol | 178 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 49 |
| Metformin Hcl | Metformin Hcl | 163 | 45 |
| Lisinopril | Lisinopril | 158 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 37 |
| Lorazepam | Lorazepam | 151 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 34 |
| Pregabalin | Pregabalin | 133 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 37 |
| Colchicine | Colchicine | 127 | 44 |
| Furosemide | Furosemide | 127 | 37 |
| Eliquis | Apixaban | 115 | 28 |
| Simvastatin | Simvastatin | 112 | 32 |
| Diazepam | Diazepam | 110 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 109 | 12 |
| Celecoxib | Celecoxib | 109 | 28 |
| Farxiga | Dapagliflozin Propanediol | 109 | 31 |
| Carvedilol | Carvedilol | 108 | 27 |
| Trazodone Hcl | Trazodone Hcl | 107 | 24 |
| Temazepam | Temazepam | 100 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 25 |
| Meloxicam | Meloxicam | 96 | 24 |
| Sertraline Hcl | Sertraline Hcl | 96 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 95 | 22 |
| Finasteride | Finasteride | 94 | 22 |
| Famotidine | Famotidine | 93 | 28 |
| Montelukast Sodium | Montelukast Sodium | 92 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 29 |
| Estradiol | Estradiol | 85 | 20 |
| Ozempic | Semaglutide | 85 | 17 |
| Spironolactone | Spironolactone | 85 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 28 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 74 | 17 |
| Mounjaro | Tirzepatide | 73 | suppressed |
| Dexamethasone | Dexamethasone | 71 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 15 |
| Jardiance | Empagliflozin | 70 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 66 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 63 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 63 | 13 |
| Bupropion Xl | Bupropion Hcl | 62 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 14 |
| Methocarbamol | Methocarbamol | 57 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 55 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 16 |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Ibuprofen | Ibuprofen | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Alendronate Sodium | Alendronate Sodium | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 11 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Clonidine Hcl | Clonidine Hcl | 35 | 12 |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Indapamide | Indapamide | 34 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 18 |
| Topiramate | Topiramate | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Prednisone | Prednisone | 30 | 13 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Mupirocin | Mupirocin | 28 | 17 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 13 |
| Azithromycin | Azithromycin | 25 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Progesterone | Progesterone, Micronized | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Nabumetone | Nabumetone | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Imiquimod | Imiquimod | 19 | 15 |
| Cephalexin | Cephalexin | 18 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $785.54 · 47 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, CARDIOMEMS, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, JOURNAVX, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, SPRAVATO, UBRELVY, UPTRAVI, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error